BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer
October 23, 2019Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …
Biogen aiming for Aducanumab to slow Alzheimer’s progression
October 23, 2019Research and Development
US firm Biogen is hoping for approval to bring about a treatment that could slow the onset of Alzheimer’s disease. …
Takeda acquires investigational coeliac disease therapy
October 23, 2019Research and Development
Takeda has acquired licensing for a first-in-class investigational coeliac disease therapy CNP-101/TAK-101. The Japanese pharma giant now has the rights …
Porton Biopharma signs potential $24m deal to push its intranasal anthrax vaccine into Phase 1 trials
October 22, 2019Manufacturing and Production, Research and Development FDA, Porton Biopharma, anthrax, pharma
Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …
Novo Nordisk opens first Pharmatech branch office in Singapore
October 22, 2019Manufacturing and Production Novo Nordisk, Singapore, pharma
Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening …
Teva offers massive $23 billion to avoid thousands of lawsuits
October 22, 2019Manufacturing and Production
Israeli drug company Teva has said that it would offer $250 million in cash and a supply of Suboxone, an …
Cancer Research UK announces push for earlier cancer detection
October 22, 2019Manufacturing and Production
Cancer Research UK has embarked on a new international alliance with a plan to develop ‘radical new strategies’ and technologies …
US FDA approves Vertex’s new breakthrough therapy for cystic fibrosis
October 22, 2019Manufacturing and Production
The US FDA has approved Trikafta (elexacaftor/ivacaftor/tezacaftor) – the first triple combination therapy available for patients with most common cystic …
“No deal” Brexit and life sciences: What happens?
October 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma
Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …
FDA approves Alexion’s Ultomiris in atypical haemolytic uremic syndrome for adults and children
October 21, 2019Sales and Marketing Alexion, FDA, Ultomiris, pharma, rare disease
The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …
CHMP recommends several drugs for EU market approval
October 21, 2019Sales and Marketing
The EMA’s human medicines committee (CHMP) has recommended seven medicines for approval at its October 2019 meet including MSD’s Ervebo, …
Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma
October 21, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
AstraZeneca receives FDA approval for Farxiga
October 21, 2019Sales and Marketing
AstraZeneca have announced that the US FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure …
GlaxoSmithKline sells two vaccines for up to £822m
October 21, 2019Sales and Marketing
GlaxoSmithKline has announced it will divest two of its major vaccines to Denmark-based Bavarian Nordic in a deal that will …
Medical cannabis: Growth by leaps and bounds
October 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Canopy Growth, medical cannabis, pharma
This article follows parts one and two of our trio of in-depth pieces focusing on the growing medical cannabis phenomenon. …
Top Ten most popular articles on Pharmafile.com this week
October 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
It’s time for a rundown of the top 10 articles on PharmaFile this past week. The past seven days saw …
2019 saw the FDA approve more generic drugs than ever before
October 18, 2019Medical Communications, Sales and Marketing FDA, US, generic drugs, pharma
Fiscal year 2019 was a record-breaking one, according to the FDA. The US regulator smashed its previous total for annual …
FDA panel gives positive vote for Shionogi’s Cefiderocol in Urinary Tract Infections
October 18, 2019Medical Communications
The US FDA has recommended approval for cefiderocol, a novel antibiotic for complicated urinary tract infections, including pyelonephritis, in patients …
FDA greenlights Genentech’s Xofluza for acute, uncomplicated influenza
October 18, 2019Medical Communications FDA, Genetech, Roche, US, Xofluza, flu, pharma
Roche subsidiary Genentech has announced that its polymerase acidic endonuclease inhibitor Xofluza (baloxavir marboxil) has been awarded FDA approval in …
MSD to cut around 500 jobs in US next year
October 18, 2019Medical Communications
MSD have announced it plans to eliminate approximately 500 jobs in multiple US states according to a filing with the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
